Literature DB >> 30889052

Opioid cessation and chronic pain: perspectives of former opioid users.

Jenna Goesling1, Melissa DeJonckheere2, Jennifer Pierce1, David A Williams1, Chad M Brummett1, Afton L Hassett1, Daniel J Clauw1.   

Abstract

Current guidelines for addressing opioid cessation in the context of chronic pain management recommend that opioids be discontinued if the risks outweigh the benefits. However, few studies have focused on understanding opioid cessation from the perspective of individuals with chronic pain. This mixed-method study included 49 former opioid users with chronic pain and used quantitative survey data and qualitative focus group data to identify themes pertaining to former opioid user's experience before, during, and after opioid cessation. Participants described several reasons for wanting to stop opioids including lack of efficacy, impact on quality of life, and concerns about addiction. Barriers to cessation included concerns about inadequate pain management and concerns about the impact of stopping opioids on mood. After opioid cessation, the sample was mixed regarding the benefit of cessation. Half of the former opioid users reported their pain to be better or the same after stopping opioids; however, 47% of the sample reported feeling worse pain since stopping their opioids. As the pendulum swings from pain control to drug control, we must ensure that the response to the opioid epidemic does not cause harm to individuals with chronic pain. Novel opioid cessation interventions are needed in combination with methods of addressing individual challenges and barriers to adequate pain relief including access to and provision of nonopioid alternatives for pain management.

Entities:  

Mesh:

Year:  2019        PMID: 30889052     DOI: 10.1097/j.pain.0000000000001493

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  Factors associated with opioid-tapering success: A mixed methods study.

Authors:  Jennifer L Kuntz; John F Dickerson; Jennifer L Schneider; Alison J Firemark; Dea Papajorgji-Taylor; Matthew Slaughter; Katherine R Reese; Lou Ann Thorsness; Mark D Sullivan; Lynn L Debar; David H Smith
Journal:  J Am Pharm Assoc (2003)       Date:  2021-01-21

2.  Changes in Outpatient Opioid Prescribing During the COVID-19 Pandemic: An Interrupted Time Series Analysis.

Authors:  Sharon Rikin; Hector R Perez; Chenshu Zhang; Laila Khalid; Justina Groeger; Yuting Deng; Joanna L Starrels
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

3.  Swallowing the pill of adverse effects: A qualitative study of patients' and pharmacists' experiences and decision-making regarding the adverse effects of chronic pain medications.

Authors:  Lise Dassieu; Emilie Paul-Savoie; Élise Develay; Ana Cecilia Villela Guilhon; Anaïs Lacasse; Line Guénette; Kadija Perreault; Hélène Beaudry; Laurent Dupuis
Journal:  Health Expect       Date:  2021-12-21       Impact factor: 3.377

4.  Evaluating acceptability and feasibility of a mobile health intervention to improve self-efficacy in prescription opioid tapering in patients with chronic pain: protocol for a pilot randomised, single-blind, controlled trial.

Authors:  Michael Magee; Ali Gholamrezaei; Amy Gray McNeilage; Leah Dwyer; Alison Sim; Manuela Ferreira; Beth Darnall; Paul Glare; Claire Ashton-James
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 3.006

5.  "They think you're trying to get the drug": Qualitative investigation of chronic pain patients' health care experiences during the opioid overdose epidemic in Canada.

Authors:  Lise Dassieu; Angela Heino; Élise Develay; Jean-Luc Kaboré; M Gabrielle Pagé; Gregg Moor; Maria Hudspith; Manon Choinière
Journal:  Can J Pain       Date:  2021-04-15

6.  The Relationship between Higher Chronic Opioid Therapy Dose and Specific Personality Traits in Individuals with Chronic Pain.

Authors:  Amanda McIntyre; Swati Mehta; Danielle Vanderlaan; Keith Sequeira; Eldon Loh; Robert Teasell
Journal:  Pain Res Manag       Date:  2021-06-28       Impact factor: 3.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.